The selection bias arises because the inclusion of patients was based on available records, which might not fully represent the broader population of HER2-positive or HER2-low breast cancer patients, potentially leading to an over- or underestimation of RC48’s efficacy and safety. This evidence concerns the gene ERBB2 and breast carcinoma.